Eli Lilly to restructure cancer research, including Boulder office

INDIANAPOLIS and BOULDER — Eli Lilly & Co. (NYSE: LLY) is consolidating its oncology research efforts into one new division, including an office in Boulder.

In a press release Thursday, Lilly said it would merge its existing Lilly Research Laboratories division with Loxo to create Loxo Oncology at Lilly. The new division will spearhead the company’s cancer research and scout other companies for future licensing or takeover deals.

The Indianapolis-based pharmaceutical giant acquired Loxo this year. Loxo is based in Stamford, Connecticut, but has an office in Boulder focused on drug development.

A Loxo spokeswoman said there are 30 employees in the Boulder office and the company plans to continue hiring there as needed.

INDIANAPOLIS and BOULDER — Eli Lilly & Co. (NYSE: LLY) is consolidating its oncology research efforts into one new division, including an office in Boulder.

In a press release Thursday, Lilly said it would merge its existing Lilly Research Laboratories division with Loxo to create Loxo Oncology at Lilly. The new division will spearhead the company’s cancer research and scout other companies for future licensing or takeover deals.

The Indianapolis-based pharmaceutical giant acquired Loxo this year. Loxo is based in Stamford, Connecticut, but has an office in Boulder focused on drug development.

A Loxo spokeswoman said there are 30 employees in the Boulder office and the company plans to continue hiring there as needed.